{"name":"Clearside Biomedical, Inc.","slug":"clearside-biomedical-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1664000,"revenueGrowth":-79.8,"grossMargin":0,"rdSpend":18590000,"netIncome":-34352000,"cash":20020000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CLS-AX","genericName":"CLS-AX","slug":"cls-ax","indication":"Other","status":"phase_2"},{"name":"SC CLS-TA","genericName":"SC CLS-TA","slug":"sc-cls-ta","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CLS-AX","genericName":"CLS-AX","slug":"cls-ax","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SC CLS-TA","genericName":"SC CLS-TA","slug":"sc-cls-ta","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHNDR2RoWGUwU3lJeHRocVBKaW5WQ09zM2xwWEQzS1JTMndGcFhUcDV0OUpsNTBycEgwVUY3YUJjZ01EOEJJOXdzaER6RF9yQncwc2txQmlGUnktdXBzNXFWVFhpREthbmlabF9vd0JCYTdyYkJnTUxaNkFsbl9tOGt0Qko4TWRmbjh0QnhQa1AtVkRESktTR2lR?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market - openPR.com","headline":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBDekwtMFpxakFLX19mUlpSWDRtcnVQNk9GbE83QTNxT19RczhzNjhnSkw4alZhMjZQZ3FBeWNreTZHTS1laWJqMURWMlUzRTM3V3hqT3QxSjlmQUxuT0V5Um1ISEdPMmYyU1JHV0Zn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Clearside Biomed (CLSD) - Stock Titan","headline":"If You Invested $1,000 in Clearside Biomed (CLSD)","sentiment":"neutral"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNQUVZbUJkQUNXYVVGajZ0X2M3UmJ4aFItZVktTFdYVzY2Qnl0c09vSlAxdVAzdV9WVExYU3lCcnh0dmJ0M3pSUjlaX2xmN1VHT2JURm9fX3R3ZXB0SzE4Wld3ZzVlSDgtQmZrSlhyRVFlUVBmU2RSM0lkV3lVclVrTjhMTk9hTDhUTXhpV2NLaS1vTm5UVkQ3R1dwRlBudl9ldG52UklkMDVoWExrMjZqVVhwamhEVHdJVW9FVE5QT19vMmdGYlZIaFlrcXJNck0?oc=5","date":"2025-12-08","type":"pipeline","source":"Investing.com","summary":"Clearside Biomedical files to delist common stock from Nasdaq after bankruptcy - Investing.com","headline":"Clearside Biomedical files to delist common stock from Nasdaq after bankruptcy","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNlBKbVpYN05QYU5sMXdwQnNVRFRaajA1TUFQUVBod3dwSlNBYlNBQkNTWGZURFNPRWNUWHptRWc4YXJvbW9SNnJ0WDJKQ1I1RWxtUU1zRlNJV0NWQkFLY3lHOWRsU1I5WlhHWkMyQzVwc0llcXJNcGpmWWlUdTlLN3V3V0ZtTFlUcTdqd2kxTkVJRG8?oc=5","date":"2025-11-25","type":"pipeline","source":"thestreet.com","summary":"Key medical device brand for files Chapter 11 bankruptcy - thestreet.com","headline":"Key medical device brand for files Chapter 11 bankruptcy","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOeEN4X0lzQ3NUS3FOQlBsbF9sTjhwUmN0SFpwS3EwZ015RU50VzZLYkowRk1uRmlwS3daMlp5aWtZeTM5QzhKTExueGdiQ09SODF6aldodXNXYlh3cklCUW1FUDlKMlk3Wm1yQ3llWW9lWkRzR3FMdGs3U0tzX01OQ3VZbGlYR1A0MDkyS18xQUZLT0x0cW1ON2xPdllZM2lWZGtmZldCbENVaHJiZzRBVC1zTHptQm1WbE5uX0NDTXZNSk81VUZLbUUwcE96blEtVTk1Mk1zQVltSlRxMnVvQmNMcHRqZmlYUlEzRTJKQkYwNlQ3d1pIS3lUblhuVWs?oc=5","date":"2025-11-24","type":"pipeline","source":"GlobeNewswire","summary":"Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewswire","headline":"Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNb0FmYmdwX2VtZllUZXNvdUZvQ1B0T0R5VXVibUV6alkxaXhKdjI0b25IQVVldS1ZNFR1cm5WeV83RDRFazQzMFllbkVzSDdwZ01zRXhTTzg4VUpjN0NmcTNMdU1BLWZ3ZWZMYTJJYW53ZnRzWDRJWURnZFdYYlA3SVg2bi1mMWhpWkZTWlpyajd2bG1uT0FRczYxbVI3YTFELUlsNVo4VnRpNWFZcDdNMm0yNld2QjlENzdWY0tKQkZZUnd2R1J2NHdIQkw4SDdPVWNSUVNuTDJMeG54RWVySklteEg4LURKd1dBeE5wRlg3U1UyZ25GbWE5UnZ3QQ?oc=5","date":"2025-05-14","type":"earnings","source":"GlobeNewswire","summary":"Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire","headline":"Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZ3M2UVJDSERLYUlKQ1MzdVpmZ1k0aGVoYnpfVlZORnpSM0h3ODJWandhOUJrNDJmMDBIUm5WaURPb01VTnU4NzNXcXE1NWk3Vk5MZjRUSDV0R0VGcFFVSFVyRHkzSGYzUWE1R2pIMWh1elRINk1vbnVIRDdsUWc2eXFZQmk?oc=5","date":"2025-05-02","type":"pipeline","source":"American Academy of Ophthalmology","summary":"Corporate and Institutional Support - American Academy of Ophthalmology","headline":"Corporate and Institutional Support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNYjAzN1A2MjVqTTd0WWNKcjc5dTNLWk1tWFQ3Y2diOTZsM2RQaV9fZnF4UjNremdqNnlUSGFNZEFtSGlnd0hJdjRvUW1LSW5CQlRtLWlHWG4zSlNJaGFsLThGNEpxX0hNTmFmbTRYclo4ODNrWWxMcGF0T1dQcDNCMUxVM3pYbnlJcE0weUdVYzNfc2ZpMVE?oc=5","date":"2025-03-27","type":"earnings","source":"Yahoo Finance","summary":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance","headline":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPc2VOc0ExejM2cTRiRjlSN2FNbzV3VmdDaFJNTjB2THZJX0VYX0dwLWV1M0Y4Q3JpRzBONGVSVHV0a25nOTJjZGdpelFtbnJubk52cFlibnZqZXR4WlpQeUV0SEFvTW5ib3g2SWlKLUxVMDdMN2FYUGNGTW5NWU1PdGhJRUNmcWMtLUpFZ3lJU1IwYkZMMnY3cFJkcWlsMy1OZ29mVWNaYWFWSHFLZmFnNmllRjFma2dJR2R0N2RRSDhtQQ?oc=5","date":"2024-11-06","type":"pipeline","source":"VisionMonday.com","summary":"Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - VisionMonday.com","headline":"Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOS29uTVFXdHpudkFQWEZHLVBpU2NuVmFabGgwazdIaE1JYjFoZUtSWWxmUGZXUE8xT3kxOEM3aG1kQmpQQWFRbzgxMng0bkY0UlNSNEdWM3NoeTdUZWlkUkI3WFV6bk13anFnWER0NE83R2tmTk81VXh6TXExaVpDSS00dXpMNV9CZ1NJZVd4eVp6eUZzT3N5c2VHRmxuUklaSFNCRE9Penh4N25rMDdUVFFYTEhPR2JVQWo2cDI0cG0tUzg?oc=5","date":"2024-10-09","type":"pipeline","source":"Fierce Pharma","summary":"Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's Eylea - Fierce Pharma","headline":"Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's Eylea","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1664000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":1664000,"period":"2024-12-31"},{"value":8226000,"period":"2023-12-31"},{"value":1327000,"period":"2022-12-31"},{"value":29575000,"period":"2021-12-31"},{"value":7894000,"period":"2020-12-31"},{"value":2173000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18590000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34352000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":20020000,"cashHistory":[],"totalAssets":25126000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}